Achilles Therapeutics

London
United Kingdom

Show jobs for this employer

About Achilles Therapeutics

Achilles intends to develop next-generation personalized vaccines and adoptive T cell therapies for metastatic cancer by targeting truncal tumor neoantigens. The company is based on research at University College London, Cancer Research UK (CRUK) and the Francis Crick Institute.
YEAR FOUNDED:
2016
LEADERSHIP:
Scientific Founder: Charles Swanton
CEO: Chris Ashton

15 articles with Achilles Therapeutics